Value
3.5/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 2.7 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 41.4x
- ▸PEG: 0.16
AXSM · Why this verdict
Why Axsome Therapeutics (AXSM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue expanded 57% year-over-year, and the combined growth-plus-profitability score of 57 is well above the 40-point threshold that indicates a business is scaling efficiently relative to its investment. This rate of expansion ranks among the strongest in the peer set. Growth breakdown | Revenue growth sustains above 40% year-over-year for the next four quarters while the combined growth-plus-profitability metric remains above 40. | →Stable |
| CounterA forward P/E near 43x and negative free cash flow price in a sustained high-growth runway; even a deceleration to a still-strong but lower growth rate could trigger sharp multiple compression given there is no earnings yield cushion at current levels. | ||
A golden cross, position above all moving averages, RSI at 68, bullish MACD, and rising on-balance volume together reflect institutional accumulation across multiple technical dimensions simultaneously — a configuration that historically supports continuation rather than immediate reversal. Momentum breakdown | Price sustains above the 200-day moving average and on-balance volume continues rising over the next six months without a death cross forming. | →Stable |
| CounterRSI approaching the 70 overbought zone and a price already trading above the analyst-derived target suggest the technical move may be close to exhaustion; at this juncture, momentum signals often precede sharp reversals rather than orderly continuations. | ||
Free cash flow is negative at -1% of revenue, and business quality sits just below the minimum threshold required for a compelling setup — the company remains cash-consuming despite 57% revenue growth, indicating it is not yet self-funding its expansion. Quality breakdown | Free cash flow turns positive and exceeds 5% of revenue for 2 consecutive quarters, confirming the business is approaching self-funding profitability. | →Stable |
| CounterA combined growth-plus-profitability score of 57 — well above the 40-point bar — indicates the business is scaling efficiently relative to its investment; the negative free cash flow may be a deliberate and time-limited choice rather than structural weakness. | ||
The current share price has moved past the analyst-derived price target, producing a negative reward-to-risk ratio — there is no upside remaining to the consensus view, and with roughly 7% downside to the risk floor, the setup is structurally unfavorable for new entries at current levels. Price targets | Analyst consensus price target rises above $295, creating more than 15% upside from current price levels and restoring a positive reward-to-risk geometry. | →Stable |
| CounterIn high-growth healthcare names, material analyst target upgrades often follow a fundamental inflection point such as the first quarter of positive free cash flow or a substantial earnings beat — both of which remain possible given the 57% revenue growth backdrop. | ||
Revenue expanded 57% year-over-year, and the combined growth-plus-profitability score of 57 is well above the 40-point threshold that indicates a business is scaling efficiently relative to its investment. This rate of expansion ranks among the strongest in the peer set.
→StableGrowth breakdown
- Expectation
- Revenue growth sustains above 40% year-over-year for the next four quarters while the combined growth-plus-profitability metric remains above 40.
CounterA forward P/E near 43x and negative free cash flow price in a sustained high-growth runway; even a deceleration to a still-strong but lower growth rate could trigger sharp multiple compression given there is no earnings yield cushion at current levels.
A golden cross, position above all moving averages, RSI at 68, bullish MACD, and rising on-balance volume together reflect institutional accumulation across multiple technical dimensions simultaneously — a configuration that historically supports continuation rather than immediate reversal.
→StableMomentum breakdown
- Expectation
- Price sustains above the 200-day moving average and on-balance volume continues rising over the next six months without a death cross forming.
CounterRSI approaching the 70 overbought zone and a price already trading above the analyst-derived target suggest the technical move may be close to exhaustion; at this juncture, momentum signals often precede sharp reversals rather than orderly continuations.
Free cash flow is negative at -1% of revenue, and business quality sits just below the minimum threshold required for a compelling setup — the company remains cash-consuming despite 57% revenue growth, indicating it is not yet self-funding its expansion.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive and exceeds 5% of revenue for 2 consecutive quarters, confirming the business is approaching self-funding profitability.
CounterA combined growth-plus-profitability score of 57 — well above the 40-point bar — indicates the business is scaling efficiently relative to its investment; the negative free cash flow may be a deliberate and time-limited choice rather than structural weakness.
The current share price has moved past the analyst-derived price target, producing a negative reward-to-risk ratio — there is no upside remaining to the consensus view, and with roughly 7% downside to the risk floor, the setup is structurally unfavorable for new entries at current levels.
→StablePrice targets
- Expectation
- Analyst consensus price target rises above $295, creating more than 15% upside from current price levels and restoring a positive reward-to-risk geometry.
CounterIn high-growth healthcare names, material analyst target upgrades often follow a fundamental inflection point such as the first quarter of positive free cash flow or a substantial earnings beat — both of which remain possible given the 57% revenue growth backdrop.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Revenue growing at 57% year-over-year with a combined growth-plus-profitability metric of 57 signals efficient scaling, and technical indicators show broad-based strength across moving averages, MACD, and on-balance volume — yet free cash flow is negative, business quality falls below the minimum acceptable threshold, and the share price already trades above the analyst-derived price target, leaving a negative reward-to-risk setup at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.2 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.1 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -1% of revenue
- ▸Rule of 40: 57 (pass)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 57% YoY
Momentum
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.8 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.4 |
- ▸Uptrend pullback (RSI 37) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 9.0 |
| Price target | 6.9 |
| erm sentiment | 5.0 |
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $26,811,108 (0.213% of mkt cap)
Peer rank
2.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 1.4 |
| growth rank | 7.2 |
Technical
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.0 |
| support resistance | 5.0 |
| 52w position | 8.8 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.0 |
| days to cover | 5.6 |
| volatility | 3.9 |
| put call | 0.0 |
| implied vol | 2.5 |
| beta | 9.4 |
| debt equity | 1.0 |
- ▸Elevated put/call: 4.76
- ▸High IV: 65%
Catalyst
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.5 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.8<4.5
- ASYMMETRY:0.3<1.5@spot
Warning (0)
none
Reward-to-Risk
0.27
Upside
+1.8%
Downside
6.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.8<4.5.
The strongest dimensions are Growth at 10.0, Sentiment at 7.2, and Technical at 6.3; the weakest are Peer rank at 2.9, Insider at 3.4, and Catalyst at 3.5. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Revenue Growth Rule Of 40
Trip ifRevenue growth decelerates below 30% year-over-year for 2 consecutive quarters.
- P2Technical Uptrend Broad Accumulation
Trip ifPrice closes below the 200-day moving average for 5 consecutive trading days.
- P3Cash Burning Quality Below Minimum
Trip ifFree cash flow turns positive and exceeds 5% of revenue for 2 consecutive quarters.
- P4Price Above Target Negative Geometry
Trip ifAnalyst consensus price target rises above $295, creating more than 15% upside from then-current price levels.